This archive contains links to the full-text of all issues of Clin Mol Hepatol.
First decision
07 Days
Publication after acceptance
03 Days
*Last 12 months
Viewed By 5842 |
Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations |
Viewed By 5266 |
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma |
Viewed By 4959 |
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma |
Viewed By 4934 |
MAFLD: How is it different from NAFLD? |
Viewed By 4562 |
Global incidence and prevalence of nonalcoholic fatty liver disease |
Cited By 202 |
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma |
Cited By 140 |
Global incidence and prevalence of nonalcoholic fatty liver disease |
Cited By 119 |
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma |
Cited By 103 |
MAFLD: How is it different from NAFLD? |
Cited By 93 |
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach |